Our website uses cookies to improve your on-site experience. By using the website, cookies are being used as described in our Policy Document
Warning: To log in you will need to enable cookies and reload the page (Policy Document)
My ePortfolio Register   

ESMO 2016 /
Olaparib and paclitaxel for 2nd line gastric cancer therapy

7th - 11th Oct 2016

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Submit
Thanks for rating
There has been a problem, please refresh and try again.
Published: 10.10.16
Views: 1589
Rating:

Dr Yung-Jue Bang - Seoul National University, Seoul, South Korea

Dr Bang speaks with ecancer at ESMO 2016 to discuss outcomes of the GOLD trial, combining olaparib and paclitaxel to treat advanced gastric cancer.

Compared to paclitaxel alone, olaparib extended overall survival and progression free survival, but did not reach a p value indicating statistical significance.

While the trial is negative, Dr Bang describes the outcomes of indicative of a role for olaparib in future studies.

ecancer's filming at ESMO 2016 has been kindly supported by Amgen through the ECMS Foundation. ecancer is editorially independent and there is no influence over content.

Previous conferences: highlights



Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

ecancer Global Foundation